Broad Label Gives Tesaro's Niraparib A Head Start In Ovarian Cancer

Tesaro takes opportunity of broad approval for Zejula (niraparib) in recurrent ovarian cancer to highlight franchise expansion opportunities in other tumor types, including PD-1 inhibitor combination studies.